Sanofi (SNY) Non-Current Receivables (2018 - 2025)
Sanofi (SNY) has disclosed Non-Current Receivables for 8 consecutive years, with $640.2 million as the latest value for Q4 2025.
- Quarterly Non-Current Receivables rose 6.99% to $640.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $640.2 million through Dec 2025, up 6.99% year-over-year, with the annual reading at $621.4 million for FY2025, 2.52% up from the prior year.
- Non-Current Receivables hit $640.2 million in Q4 2025 for Sanofi, up from $598.4 million in the prior quarter.
- In the past five years, Non-Current Receivables ranged from a high of $640.2 million in Q4 2025 to a low of $200.2 million in Q4 2021.
- Historically, Non-Current Receivables has averaged $377.6 million across 5 years, with a median of $246.9 million in 2022.
- Biggest five-year swings in Non-Current Receivables: crashed 32.3% in 2021 and later surged 195.84% in 2024.
- Year by year, Non-Current Receivables stood at $200.2 million in 2021, then increased by 23.33% to $246.9 million in 2022, then decreased by 18.07% to $202.3 million in 2023, then soared by 195.84% to $598.4 million in 2024, then rose by 6.99% to $640.2 million in 2025.
- Business Quant data shows Non-Current Receivables for SNY at $640.2 million in Q4 2025, $598.4 million in Q4 2024, and $202.3 million in Q4 2023.